Mycenax Biotech (4726) — Capital Reinvestment Ratio

Latest as of March 2025: 5.90x

Mycenax Biotech (4726) has a Capital Reinvestment Ratio of 5.90x as of March 2025, meaning it reinvests 6% of its operating cash flow (NT$14.29 Million) in capital expenditures (NT$84.30 Million). See Mycenax Biotech net asset quality index to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

5.90x
Capex / Operating Cash Flow

Operating Cash Flow

NT$14.29 Million
TWD

Capital Expenditures

NT$84.30 Million
TWD

Data as of

Mar 2025
Most recent filing

Mycenax Biotech Capital Reinvestment Ratio (2020–2020)

This chart tracks Mycenax Biotech's Capital Reinvestment Ratio across 1 annual periods. Check Mycenax Biotech investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Mycenax Biotech (2020–2020)

Year-by-year Capital Reinvestment Ratio for Mycenax Biotech from 2020 to 2020. For live market cap and broader valuation context, see Mycenax Biotech market capitalisation.

Year Reinvestment Ratio Operating CF (TWD) Capital Expenditures YoY Change
2020 1.49x NT$174.17 Million NT$260.22 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow